Document is current

Any future updates will be listed below

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

Crossref DOI link: https://doi.org/10.1186/s13098-016-0169-x

Published Online: 2016-07-26

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark